Your browser doesn't support javascript.
loading
The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases - A multicenter cohort study.
Holmberg, Carl-Jacob; Ny, Lars; Hieken, Tina J; Block, Matthew S; Carr, Michael J; Sondak, Vernon K; Örtenwall, Christoffer; Katsarelias, Dimitrios; Dimitriou, Florentia; Menzies, Alexander M; Saw, Robyn Pm; Rogiers, Aljosja; Straker, Richard J; Karakousis, Giorgos; Applewaite, Rona; Pallan, Lalit; Han, Dale; Vetto, John T; Gyorki, David E; Tie, Emilia Nan; Vitale, Maria Grazia; Ascierto, Paulo A; Dummer, Reinhard; Cohen, Jade; Hui, Jane Yc; Schachter, Jacob; Asher, Nethanel; Helgadottir, H; Chai, Harvey; Kroon, Hidde; Coventry, Brendon; Rothermel, Luke D; Sun, James; Carlino, Matteo S; Duncan, Zoey; Broman, Kristy; Weber, Jeffrey; Lee, Ann Y; Berman, Russell S; Teras, Jüri; Ollila, David W; Long, Georgina V; Zager, Jonathan S; van Akkooi, Alexander; Olofsson Bagge, Roger.
Afiliación
  • Holmberg CJ; Sahlgrenska Center for Cancer Research, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Sweden; Department of Surgery, Sahlgrenska University Hospital, Gothenburg,
  • Ny L; Sahlgrenska Center for Cancer Research, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Hieken TJ; Department of Surgery, Mayo Clinic, Rochester, USA; Mayo Clinic Cancer Center, Rochester, USA.
  • Block MS; Mayo Clinic Cancer Center, Rochester, USA; Department of Oncology, Mayo Clinic, Rochester, USA.
  • Carr MJ; Department of Cutaneous Oncology Moffitt Cancer Center, Tampa, USA.
  • Sondak VK; Department of Cutaneous Oncology Moffitt Cancer Center, Tampa, USA.
  • Örtenwall C; Sahlgrenska Center for Cancer Research, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Katsarelias D; Sahlgrenska Center for Cancer Research, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Dimitriou F; Melanoma Institute Australia, The University of Sydney, Sydney Australia; Department of Dermatology, University Hospital of Zürich, Zürich, Switzerland.
  • Menzies AM; Melanoma Institute Australia, The University of Sydney, Sydney Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Royal North Shore and Mater Hospitals, Sydney, Australia.
  • Saw RP; Melanoma Institute Australia, The University of Sydney, Sydney Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, Australia.
  • Rogiers A; Melanoma Institute Australia, The University of Sydney, Sydney Australia.
  • Straker RJ; Department of Surgery, University of Pennsylvania, Perelman School of Medicine, Philadelphia, USA.
  • Karakousis G; Department of Surgery, University of Pennsylvania, Perelman School of Medicine, Philadelphia, USA.
  • Applewaite R; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Pallan L; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Han D; Division of Surgical Oncology, Department of Surgery, Oregon Health & Science University, Portland, USA.
  • Vetto JT; Division of Surgical Oncology, Department of Surgery, Oregon Health & Science University, Portland, USA.
  • Gyorki DE; Division of Cancer Surgery, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department, University of Melbourne, Melbourne, Australia.
  • Tie EN; Division of Cancer Surgery, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department, University of Melbourne, Melbourne, Australia.
  • Vitale MG; Department of Skin Cancers, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy.
  • Ascierto PA; Department of Skin Cancers, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy.
  • Dummer R; Department of Dermatology, University Hospital of Zürich, Zürich, Switzerland.
  • Cohen J; Department of Surgery, University of Minnesota, Minneapolis, USA.
  • Hui JY; Department of Surgery, University of Minnesota, Minneapolis, USA.
  • Schachter J; The Ella Lemelbaum Institite for Immuno-oncology, Sheba Medical Center, Tel Aviv, Israel.
  • Asher N; The Ella Lemelbaum Institite for Immuno-oncology, Sheba Medical Center, Tel Aviv, Israel.
  • Helgadottir H; Theme Cancer, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden.
  • Chai H; Department of Surgery, Royal Adelaide Hospital, Adelaide, Australia; Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia.
  • Kroon H; Department of Surgery, Royal Adelaide Hospital, Adelaide, Australia; Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia.
  • Coventry B; Department of Surgery, Royal Adelaide Hospital, Adelaide, Australia; Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia.
  • Rothermel LD; Department of Surgery, University Hospitals Cleveland Medical Center, Cleveland, USA; Case Western Reserve University, Cleveland, USA.
  • Sun J; Department of Surgery, University Hospitals Cleveland Medical Center, Cleveland, USA; Case Western Reserve University, Cleveland, USA.
  • Carlino MS; Melanoma Institute Australia, The University of Sydney, Sydney Australia; Department of Medical Oncology, Westmead and Blacktown Hospitals, The Crown Princess Mary Cancer Centre, Sydney, Australia.
  • Duncan Z; University of Alabama at Birmingham, Birmingham, USA.
  • Broman K; University of Alabama at Birmingham, Birmingham, USA.
  • Weber J; Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York, USA.
  • Lee AY; Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York, USA; NYU Grossman School of Medicine, Department of Surgery, New York, USA.
  • Berman RS; Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York, USA; NYU Grossman School of Medicine, Department of Surgery, New York, USA.
  • Teras J; North Estonian Medical Centre Foundation, Tallinn, Estonia.
  • Ollila DW; Division of Surgical Oncology and Endocrine Surgery, University of North Carolina at Chapel Hill, Chapel Hill, USA.
  • Long GV; Melanoma Institute Australia, The University of Sydney, Sydney Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Royal North Shore and Mater Hospitals, Sydney, Australia.
  • Zager JS; Department of Cutaneous Oncology Moffitt Cancer Center, Tampa, USA; Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, USA.
  • van Akkooi A; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Olofsson Bagge R; Sahlgrenska Center for Cancer Research, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Sweden; Department of Surgery, Sahlgrenska University Hospital, Gothenburg,
Eur J Cancer ; 169: 210-222, 2022 07.
Article en En | MEDLINE | ID: mdl-35644725
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Inhibidores de Puntos de Control Inmunológico / Melanoma Tipo de estudio: Etiology_studies / Guideline / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Eur J Cancer Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Inhibidores de Puntos de Control Inmunológico / Melanoma Tipo de estudio: Etiology_studies / Guideline / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Eur J Cancer Año: 2022 Tipo del documento: Article